Glaukos Corporation — Third Quarter 2026 Earnings Summary

Glaukos Corporation reported record third-quarter 2026 net sales of $211.0 million, representing a 58% year-over-year increase driven by strong performance in both U.S. Glaucoma and Corneal Health segments. The company achieved a GAAP net income of $2.0 million and a non-GAAP net income of $28.5 million, with gross margins reaching approximately 85%. Management raised its full-year 2026 net sales guidance to a range of $775 million to $785 million and introduced preliminary 2027 guidance of $1 billion. Additionally, the company ended the quarter with $339.8 million in cash and cash equivalents, short-term investments, and restricted cash.